Strathprints Home | Open Access | Browse | Search | User area | Copyright | Help | Library Home | SUPrimo

Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?

Wilson, C. G. and O'Mahony, B. and Connolly, S. M. and Cantarini, M. V. and Farmer, M.R. and Dickinson, P.A. and Smith, R. P. and Swaisland, H.C. (2009) Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib? International Journal of Pharmaceutics, 376 (1-2). pp. 7-12. ISSN 0378-5173

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

The selective EGFR tyrosine kinase inhibitor, gefitinib has been shown to be active against certain human carcinomas. It had been noted that a proportion of volunteers consistently had lower gefitinib exposure following oral administration. The shape of the elimination profile in this subset was also different, showing a monophasic elimination pattern rather than the biphasic pattern observed in the majority of subjects. A gamma scintigraphic study was conducted to examine the relationship of gastrointestinal transit and drug absorption in a cohort of rapid clearance subjects (n = 5) and normal profile volunteers (n = 7). The fasted volunteer panel received a 250 mg gefitinib tablet labelled with [111In]–DTPA together with 240 mL [99mTc]-labelled water. The rapid clearance cohorts were shown to have a faster mean gastric emptying T90 (37 min vs 74 min) and shorter small intestinal transit time (156 min vs 204 min), resulting in an earlier colonic arrival time (181 min vs 244 min). Mean plasma Cmax was lower (99.2 ng/mL vs 116 ng/mL) and AUC almost half in the rapid clearance group (2162 ± 81 ngh/mL vs 4996 ± 64 ngh/mL). These data suggest that gastrointestinal transit parameters play a role in the differences in the rapid clearance profile group, also contributing to the biphasic to monophasic switch. However, historical data show, at the recommended dose of 250 mg/day steady-state plasma concentrations adequate for clinical benefit are achieved in patients with non-small cell lung cancer.

Item type: Article
ID code: 34794
Keywords: gefitinib, Iressa®, gastrointestinal transit, gamma scintigraphy, Pharmacy and materia medica
Subjects: Medicine > Pharmacy and materia medica
Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences > Pharmaceutical Sciences
Related URLs:
    Depositing user: Pure Administrator
    Date Deposited: 19 Oct 2011 18:35
    Last modified: 05 Nov 2012 17:00
    URI: http://strathprints.strath.ac.uk/id/eprint/34794

    Actions (login required)

    View Item